Table 1 Demographics and clinical characteristics

From: High-resolution mapping of substantia nigra in Parkinson’s disease using 7 tesla magnetic resonance imaging

 

MT CNR

R2*

QSM

 

PD (N = 42)

HC (N = 24)

p

PD (N = 32)

HC (N = 21)

p

PD (N = 36)

HC (N = 23)

p

Age (years)

67.5 (38, 84)

71.5 (43, 80)

0.557

67 (38.79)

71 (43, 76)

0.623

66.5 (38, 80)

71 (43, 80)

0.33

Sex (male/female)

23/19

16/8

0.49

18/14

15/6

0.41

21/15

16/7

0.55

Time from onset (years)

6.06 (0.980, 18.3)

–

–

5.69 (1.84, 18.3)

–

–

5.69 (1.84, 16.8)

–

–

LEDc (mg/day)

479 (100, 2140)

–

–

479 (100, 2140)

–

–

460 (100, 2140)

–

–

Most affected side (right/left)

17/25

–

–

12/20

–

–

15/21

–

–

UPDRS-III

23.4 ± 9.27

–

–

24.2 ± 9.20

–

–

24.1 ± 9.34

–

–

NMSSe

31.0 (3, 118)

–

–

33.0 (3, 118)

–

–

30.5 (3, 118)

–

–

MoCAd

28 (17, 30)

28 (23, 31)

0.37

28 (17, 30)

28 (23, 31)

0.62

28 (17, 30)

28 (25, 31)

0.17

BDI-IIa

8 (0, 20)

3 (0, 11)

0.001*

9 (0, 20)

3 (0, 11)

0.003*

6.5 (0, 20)

3 (0, 11)

<0.001*

LARSb

−22.4 ± 6.09

−25.5 ± 4.93

0.03*

−21.6 ± 5.96

−25.3 ± 4.91

0.02*

−22.4 ± 6.20

−25.5 ± 5.04

0.04*

  1. Between group differences were assessed using Student’s t test for normally distributed data (data reported as mean ± SD) and Wilcoxon rank-sum test when normal distribution could not be assumed (data reported as median (range)). Between group differences in sex distribution were assessed using Pearson’s Chi-squared test with Yates’ continuity correction.
  2. *p < 0.05.
  3. aBDI-II: Beck’s Depression Inventory score.
  4. bLARS: Lille Apathy Rating Scale score.
  5. cLED: Levodopa Equivalent Dose.
  6. dMoCA: Montreal Cognitive Assessment score.
  7. eNMSS: Non-motor symptom scale score.
Back to article page